Stevanato Group (NASDAQ:STVN) reported a profit of $27.9 million for the first quarter of 2025, marking a solid start to the year.
On a per-share basis, the company posted earnings of 11 cents, exceeding analysts' expectations of 10 cents per share.
The company, known for manufacturing glass vials for COVID-19 vaccines, also saw its revenue rise to $269.9 million during the period, surpassing the average revenue estimate of $269.3 million provided by analysts surveyed by Zacks Investment Research.
Stevanato's performance reflects its ongoing strength in the pharmaceutical sector, where its expertise in glass vial production plays a crucial role in supporting global vaccine distribution.
Looking ahead, Stevanato expects to achieve full-year earnings in the range of 53 cents to 57 cents per share.
The company also anticipates revenue for the year to fall between $1.22 billion and $1.25 billion, driven by continued demand for its products and services in the healthcare industry.